Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 255

Similar articles for PubMed (Select 19696042)

1.

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Stangier J, Clemens A.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19. Review.

PMID:
19696042
2.

Dabigatran etexilate: future directions in anticoagulant treatment.

Schulman S, Reilly PA.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:32S-41S. doi: 10.1177/1076029609344199. Epub 2009 Aug 13. Review.

PMID:
19679590
3.
4.

Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.

Dahl OE.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:17S-24S. doi: 10.1177/1076029609344588. Epub 2009 Aug 19. Review.

PMID:
19696041
5.

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.

Eriksson BI, Friedman RJ.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31. Review.

PMID:
19648146
6.

Oral antithrombotic inhibitors: dabigatran etexilate, meeting an unmet need?

Hull R.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:5S-8S. doi: 10.1177/1076029609344427. Epub 2009 Aug 24.

PMID:
19706619
7.

[Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].

Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I.

Farm Hosp. 2009 May-Jun;33(3):125-33. Spanish.

PMID:
19712596
8.

Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.

Garza R, Huo MH.

Expert Rev Cardiovasc Ther. 2012 Apr;10(4):423-7. doi: 10.1586/erc.12.15. Review.

PMID:
22458575
9.

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Stangier J, Stähle H, Rathgen K, Fuhr R.

Clin Pharmacokinet. 2008;47(1):47-59.

PMID:
18076218
10.

New options with dabigatran etexilate in anticoagulant therapy.

Maegdefessel L, Spin JM, Azuma J, Tsao PS.

Vasc Health Risk Manag. 2010 May 25;6:339-49. Review.

11.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082
12.

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

Eriksson BI, Dahl OE, Ahnfelt L, Kälebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V.

J Thromb Haemost. 2004 Sep;2(9):1573-80.

PMID:
15333033
13.

Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate.

Härtter S, Yamamura N, Stangier J, Reilly PA, Clemens A.

Thromb Haemost. 2012 Feb;107(2):260-9. doi: 10.1160/TH11-08-0551. Epub 2011 Dec 21.

PMID:
22186806
14.

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.

Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R.

J Clin Pharmacol. 2005 May;45(5):555-63.

PMID:
15831779
15.

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J.

Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29. Review.

16.

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.

Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W.

Am J Cardiovasc Drugs. 2009;9(1):59-68. doi: 10.2165/00129784-200909010-00006.

PMID:
19178132
17.

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A.

Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Review.

PMID:
20352166
18.

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W.

Br J Clin Pharmacol. 2007 Sep;64(3):292-303. Epub 2007 May 15.

19.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
20.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk